NASDAQ:VERA Vera Therapeutics Q2 2026 Earnings Report $33.05 -3.21 (-8.85%) Closing price 04:00 PM EasternExtended Trading$33.18 +0.14 (+0.41%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vera Therapeutics EPS ResultsActual EPS-$1.52Consensus EPS -$1.58Beat/MissBeat by +$0.06One Year Ago EPS-$1.20Vera Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$1.28 millionBeat/MissN/AYoY Revenue GrowthN/AVera Therapeutics Announcement DetailsQuarterQ2 2026Date8/10/2026TimeAfter Market ClosesConference Call DateMonday, August 10, 2026Conference Call Time4:00PM ETUpcoming EarningsVera Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vera Therapeutics Earnings HeadlinesAnalysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Vera Therapeutics (VERA)September 17, 2026 | theglobeandmail.comVera Therapeutics (VERA) Says TRUTAKNA Met All Phase III EndpointsSeptember 17, 2026 | finance.yahoo.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.September 23 at 1:00 AM | The Oxford Club (Ad)Vera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comVera set up for full approval for Trutakna in IgAN with Phase III winSeptember 15, 2026 | msn.comVera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial EndpointsSeptember 15, 2026 | finance.yahoo.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing treatments for immune-mediated diseases. The company’s research is centered on therapies designed to address the underlying causes of autoimmune conditions rather than primarily managing their symptoms. Vera’s leading product candidate is atacicept, an investigational biologic designed to inhibit two proteins involved in the survival and activity of antibody-producing immune cells, B-cell activating factor and a proliferation-inducing ligand. The company is evaluating atacicept primarily as a potential treatment for IgA nephropathy, a chronic autoimmune kidney disease, in the global Phase 3 ORIGIN clinical trial. Vera Therapeutics is headquartered in the San Francisco Bay Area and conducts development activities and clinical studies through sites in the United States and other international markets. As a clinical-stage company, Vera does not currently have an approved commercial product; its business is focused on research, clinical development and potential regulatory approval of therapies for patients with serious immune-mediated diseases.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Energy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock?Thor Industries Is Boring—And That May Be Its Biggest AdvantageAutoZone Shifts Gears, On Track to Reverse Course and Price RecoveryMeta’s Muse Highlights Arm’s Growing Role in AI InfrastructureOld Dogs, New Tech: 3 Legacy Stocks Powering the AI Boom Upcoming Earnings Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
